Communiqués Biosergen AB

Actions

BIOSGN

SE0026821852

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 08/05/2026			Varia. 5j.	Varia. 1 janv.
9,650 ^SEK	-0,52%		-2,03%	-75,58%

05/04	Biosergen envisage la cession de son candidat-médicament antifongique face à des difficultés de financement	MT
04/04	Biosergen suspend le développement du Bsg005	RE

Communiqués

08/04	Biosergen halts BSG005 development	AQ
04/04	Biosergen Pauses Development of BSG005	AQ
10/02	Biosergen publishes interim report for the fourth quarter 2025	AQ
20/11	Determination of Record Date for Reverse Share Split in Biosergen	AQ
19/11	Biosergen comments on continued progress in the third quarter	AQ
19/11	Biosergen publishes interim report for the third quarter 2025	AQ
28/10/25	Biosergen's Nomination Committee appointed	AQ
22/09/25	ECDC sounds alarm on C. auris – Biosergen eyes role in containment	AQ
17/09/25	Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe	AQ
02/09/25	Research update Biosergen: Ongoing development going according to plan	AQ
21/08/25	Biosergen’s CEO on the preparations for the next clinical phase	AQ
20/08/25	Biosergen publishes its interim report for the second quarter 2025	AQ
25/07/25	Biosergen strengthens executive team amid clinical momentum	AQ
24/07/25	Biosergen Appoints Mark Beveridge as Chief Financial Officer	AQ
11/06/25	Bulletin from the annual general meeting in Biosergen AB (publ)	AQ
23/05/25	Research update Biosergen: Stable quarter with exciting news around the corner	AQ
21/05/25	Biosergen publishes interim report for the first quarter 2025	AQ
12/05/25	Biosergen taps antifungal expert as board member	AQ
09/05/25	Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives	AQ
09/05/25	Notice of annual general meeting in Biosergen AB	AQ
09/05/25	BioStock: Biosergen takes aim at climate-driven fungal infections	AQ
02/05/25	BioStock: Biosergen's CEO on the latest advancements	AQ
30/04/25	Biosergen publishes 2024 annual report	AQ
07/03/25	Research update Biosergen: Continued success in India and cash injection	AQ
07/03/25	BioStock: Biosergen scales up for future wins	AQ